Do Us Payers Consider Cost-Effectiveness when Defining Prescription Benefits? A Study of Targeted Therapies for Rheumatoid Arthritis and Moderate-To-Severe Psoriasis

May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.1723
https://www.valueinhealthjournal.com/article/S1098-3015(18)32045-X/fulltext
Section Title :
Section Order : 956
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)32045-X&doi=10.1016/j.jval.2018.04.1723
HEOR Topics :
Tags :
Regions :